ArticleLangenbeck's archives of surgery2026
Impact of enhanced recovery after surgery (ERAS) on postoperative morbidity and long-term survival in patients with perihilar cholangiocarcinoma.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEnhanced Recovery After Surgery (ERAS) is a multimodal perioperative care pathway designed to improve surgical outcomes and has been widely adopted across surgical disciplines. This study evaluated the impact of adherence to ERAS Society recommendations on postoperative complications and survival in patients undergoing surgery for perihilar cholangiocarcinoma (PCH).
methodsA total of 168 patients with PCH who underwent extended liver surgery with hepatobiliary reconstruction between 2014 and 2024 were included. Of these, 94 patients were treated according to the official ERAS protocol, while 74 patients treated prior to ERAS program implementation served as the control group (Non-ERAS). The ERAS program followed strictly the official ERAS Society guidelines. Patients were analyzed with regard to postoperative complications, adherence to ERAS measures, and long-term survival.
resultsERAS was associated with a significant reduction in overall complications (Clavien-Dindo grades 1-5), Non ERAS 97.3% vs. ERAS 83.0% (p = 0.003). Within the ERAS group, lower complication rates were observed in patients with higher adherence (≥ 50%) compared to those with lower adherence (< 50%), 78.2% vs. 100% (p = 0.031). Overall adherence in the ERAS group was 64.3%, with the highest adherence seen for preoperative items (80.7%). When ERAS was coordinated by dedicated ERAS staff, overall survival was significantly improved compared to the non-ERAS group (p = 0.037). However, this association was no longer observed after multivariable adjustment. Instead, the administration of adjuvant chemotherapy and younger age emerged as independent predictors of prolonged survival.
conclusionsImplementation of the ERAS program in patients undergoing extended liver resection for PCH is feasible and safe. It was associated with a reduction in postoperative complications and a trend towards improved overall survival. These effects were most pronounced when the ERAS protocol was guided and supervised by dedicated ERAS staff.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.